Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation

Fionnuala Ni Ainline,1 Roger J. S. Preston,1 P. Vincent Jenkins,1 Hendrik J. Nel,2 Jennifer A. Johnson,1 Owen P. Smith,3 Barry White,4 Padraic G. Fallon,2 and James S. O’Donnell1,4

1Haemostasis Research Group, and 2Inflammation and Immunity Research Group, Institute of Molecular Medicine, St James’s Hospital, Trinity College, Dublin; 3Department of Haematology, Our Lady’s Children’s Hospital, Dublin; and 4National Centre for Hereditary Coagulation Disorders, St James’s Hospital, Dublin, Republic of Ireland

Protamine sulfate is a positively charged polypeptide widely used to reverse heparin-induced anticoagulation. Paradoxically, prospective randomized trials have shown that protamine administration for heparin neutralization is associated with increased bleeding, particularly after cardiothoracic surgery with cardiopulmonary bypass. The molecular mechanism(s) through which protamine mediates this anticoagulant effect has not been defined. In vivo administration of pharmacologic doses of protamine to BALB/c mice significantly reduced plasma thrombin generation and prolonged tail-bleeding time (from 120 to 199 seconds). Similarly, in pooled normal human plasma, protamine caused significant dose-dependent prolongations of both prothrombin time and activated partial thromboplastin time. Protamine also markedly attenuated tissue factor-initiated thrombin generation in human plasma, causing a significant decrease in endogenous thrombin potential (41% ± 7%). As expected, low-dose protamine effectively reversed the anticoagulant activity of unfractionated heparin in plasma. However, elevated protamine concentrations were associated with progressive dose-dependent reduction in thrombin generation. To assess the mechanism by which protamine mediates down-regulation of thrombin generation, the effect of protamine on factor V activation was assessed. Protamine was found to significantly reduce the rate of factor V activation by both thrombin and factor Xa. Protamine mediates its anticoagulant activity in plasma by down-regulation of thrombin generation via a novel mechanism, specifically inhibition of factor V activation. (Blood. 2009;114:1658-1665)

Introduction

Protamine sulfate is a 5-kDa cationic polypeptide derived from salmon sperm that can bind negatively charged unfractionated heparin (UFH).1 Although the mechanisms of the molecular interaction between protamine and heparin are not well defined, this binding serves to neutralize the antithrombin-mediated anticoagulant properties of heparin. Moreover, the resultant protamine-heparin complex is rapidly cleared by the reticuloendothelial system.2 Consequently, for more than 30 years, protamine has been widely used to reverse the anticoagulant effects of UFH. Protamine is considered the treatment of choice for patients who develop significant bleeding complications while on UFH.3,4 Furthermore, protamine is routinely administered postoperatively to reverse the high concentrations of UFH required for patients undergoing cardiac surgery and cardiopulmonary bypass (CPB).5 As a result, estimates suggest that more than 2 million heparinized patients are managed with protamine each year.2

Clinical use of protamine is, however, associated with several important adverse side effects, including potentially life-threatening systemic arterial hypotension and pulmonary artery hypertension.1 Paradoxically, in vitro studies have also suggested that protamine may possess intrinsic anticoagulant properties.6-8 Administration of excess protamine in the neutralization of UFH has been associated with increased bleeding in clinical settings, particularly after cardiothoracic surgery.9 Due to concerns regarding the inherent anticoagulant potential of protamine, current consensus guidelines recommend that the dose of protamine is limited to 1 mg protamine per 100 IU heparin.3,4 However, pharmacokinetic studies have demonstrated that protamine is cleared rapidly from human plasma (half life 7.4 minutes), so that repeated doses may be necessary to prevent rebound heparin anticoagulant effects.10,11 Animal studies have shown that although protamine fully neutralizes the thrombin-inhibitory activity of low molecular weight heparins (LMWH), it can only partially neutralize their anti–factor Xa (FXa) activities.12,13 Therefore, the clinical efficacy of protamine for reversing LMWH-induced anticoagulation remains unclear.4

Despite the widespread use of protamine in clinical practice, the molecular mechanism(s) underlying its associated intrinsic anticoagulant effect is not clearly defined. Previous studies in which incremental concentrations of protamine (50-300 μg/mL) were added to heparinized patient samples ex vivo demonstrated that heparin anticoagulation was maximally reversed at a protamine to heparin ratio of 1.3:1.8,11 However, addition of higher protamine:heparin ratios (ie, excess free protamine) resulted in significant prolongation of the activated clotting time (ACT) through an unidentified mechanism.8 Similarly, ex vivo addition of protamine to normal pooled plasma markedly attenuated tissue factor (TF)–initiated thromboelastography.14 Protamine significantly increased clot initiation time (R time), decreased the rate of clot propagation.
Protamine is a cationic polypeptide that interferes with the activation of factor X (FX) by directly neutralizing acidic phospholipids and promoting FXa and factor IX (FIX) activation. This study aimed to investigate the mechanism of protamine's anticoagulant effect and its potential therapeutic applications.

**Methods**

**Materials**

Protamine sulfate and tinzaparin (Innohep) were obtained from Leo Pharma. Unfractionated heparin, enoxaparin (Clexane), and danaparoid (Orgaran) were from Sigma-Aldrich, Sanofi-Aventis, and Schering-Plough, respectively. BALB/c mice were purchased from Harlan. Animals were housed in a pathogen-free facility using individually ventilated and filtered cages under positive pressure. All animal experiments were performed in compliance with Irish Department of Health and Children regulations and approved by the Trinity College Dublin BioResources ethical review board. Purified human activated protein C (APC), FV, FVIIIa, FVIII, and prothrombin were purchased from Haematologics Technologies. Purified human thrombin was obtained from Enzyme Research Laboratories, and phospholipid vesicles were from Avanti Polar Lipids. Synthetic cationic substrates BIOPHREN CS-21(66) and BIOPHREN CS-01(38) for APC and thrombin, respectively, were sourced from HYPHEN Biomed. Thrombin generation assay reagents (platelet-poor-plasma reagent, fluorescent substrate, thrombin calibration standard) were purchased from Thrombinoscope BV. HemosIL FVIII-deficient plasma was from Instrumentation Laboratory, and factor VIII (FVIII)–deficient plasma from Technoclone. The anticoagulant function of protamine in normal, platelet-poor, pooled plasma was assessed using a Fluoroskan Ascent plate reader (Thermo Lab System) in combination with Thrombinoscope software (Thrombinoscope BV), as previously described. Briefly, 80 µL of plasma was incubated with 20 µL of platelet-poor-plasma reagent containing 5 pM TF and 4 µM phospholipids (composed of 60% phosphatidylcholine [PC], 20% phosphatidylethanolamine [PE], and 20% phosphatidylylserine [PS], and 20% phosphatidylethanolamine [PE] in the presence or absence of protamine [3-80 µg/mL; all final concentrations]). Thrombin generation was initiated by automatic dispensation of fluorescent thrombin substrate (Z-Gly-Gly-Arg-AMC.HCl) and 100 nM CaCl₂ into each well (final concentrations, Z-Gly-Gly-Arg-AMC.HCl, 0.42 mM and CaCl₂, 16.67 mM). Thrombin generation was determined using a thrombin calibration standard. Measurements were taken at 20-second intervals for 60 minutes, or until thrombin generation was complete. The lag time to start of thrombin generation, peak amount of thrombin generated, time to peak thrombin (TTP), and area under the thrombin generation curve, represented by endogenous thrombin potential (ETP), were measured. Experiments were performed in triplicate, and data were reported as mean plus or minus SEM.

**Characterization of APC-mediated FVa proteolysis in the presence of protamine**

FVa degradation by APC was assessed, as previously described. A total of 8 nM APC was incubated at 37°C with phospholipid vesicles (PC:PS:PE 60%:20%:20%; Avanti Polar Lipids) and 4 nM FVAs (Hematologic Technologies) in the presence and absence of protamine sulfate (3 µg/mL final concentration) in 40 mM Tris-HCl, 140 mM NaCl, 3 mM CaCl₂, and 0.3% wt/vol bovine serum albumin (2 nM APC, 19 mM phospholipids, and 1 nM FVAs, final concentration). Phospholipid vesicles (PC:PS:PE 60%:20%:20%) were prepared, as described previously. At specified time points, more than 20 minutes, 2-µL aliquots were removed and added to a prothrombinase mixture (25 µM phospholipids, 1 nM FXa, and 0.5 µM prothrombin [Hematologic Technologies], final concentrations) for 3 minutes. Each reaction was stopped using 5 µL ice-cold 0.5 M EDTA (ethylenediaminetetraacetic acid). A total of 100 µL reaction mixture was removed and incubated with 100 µL of 2 mM thrombin chromogenic substrate BIOPHREN CS-01(38) (HYPHEN Biomed) to assess thrombin generation. The rate of chromogenic substrate cleavage was measured at 405 nm using a VERSAmax microplate reader (Molecular Devices). Residual FVa activity was determined by comparison with FVa activity observed before APC incubation, and plotted values represent the mean of at least 3 individual experiments plus or minus SEM.

**Characterization of APC-mediated FVIIIa proteolysis in the presence of protamine**

To determine whether protamine enhancement of APC anticoagulant activity was mediated through increased rate of FVIIIa proteolysis, we used a previously characterized APC-resistant FVIII double mutant (R336Q/R562Q; APCR-FVIII), and FVIII-deficient plasma (Technoclone) was spiked with both B-domainless wild-type FVIII (wt-FVIII) or the APCR-FVIII variant (both final concentration 1.0 U/mL [300 ng/mL]). Thrombin generation was then initiated with 5 pM TF, 4 µM phospholipid vesicles (PC:PS:PE 60%:20%:20%), and CaCl₂, and ETP was determined. Subsequently, the anticoagulant effect of protamine alone (3 µg/mL), APC alone (10 nM), or protamine in the presence of APC was determined for wt-FVIII and the APCR-FVIII variant, as before.
Clotting assay.

The effect of protamine on FV activation was determined using a method previously described by Safa et al. Briefly, purified FV (100 nM final concentration) was incubated with purified α-thrombin (1 nM final concentration) in 100 mM NaCl, 20 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; pH 7.5), 5 mM CaCl₂, and 0.2 mg/mL bovine serum albumin, or with purified FXa (20 nM final concentration) and phospholipid vesicles (80 μM final concentration). At specific time intervals, aliquots were removed and diluted in 100 mM NaCl and 20 mM Tris-HCl (pH 7.5) to stop FV activation. The time course of FV activation was immediately quantified using FV-deficient plasma in a standard prothrombin-based clotting assay.

**Results**

**Protamine prolongs in vivo bleeding time in mice and has a concentration-dependent anticoagulant effect in plasma**

After intravenous administration of a therapeutic protamine dose (50 mg), pharmacokinetic studies have demonstrated typical plasma protamine levels of up to 50 μg/mL. However, in practice, doses exceeding 5 mg/kg are frequently administered. In BALB/c mice, we observed that parenteral protamine (5 mg/kg) administration significantly prolonged tail-bleeding time and attenuated thrombin generation (Figure 1A-B). These findings, which are in keeping with a previous report in which intravenous protamine (1.5 mg/kg) prolonged the ACT and APTT in a canine model, confirm that protamine has in vivo anticoagulant activity. In addition, the presence of protamine in normal pooled human plasma resulted in significant prolongations in the APTT and PT, respectively (Figure 1C-D). Furthermore, again in keeping with previous reports, protamine (5-60 μg/mL) also significantly prolonged human whole blood ACT (data not shown). In contrast, although previous studies demonstrated that protamine can bind fibrinogen, we observed no effect of protamine (final concentration 5-50 μg/mL) on thrombin-clotting time (data not shown).

Calibrated automated thrombography was used to assess the impact of protamine on TF-initiated thrombin generation. In normal plasma, protamine significantly reduced thrombin generation (Figure 2A). Calculation of ETP demonstrated that 30 μg/mL protamine reduced thrombin generation to 59% (± 7%; P < .05) of the original ETP before protamine incubation (Figure 2B). Furthermore, at pharmacologic doses, protamine significantly influenced all of the individual parameters assessed during thrombin generation, with significant prolongation of lag time and TTP and a marked decrease in peak thrombin generation (Figure 2B), suggesting that protamine may influence the initiation and propagation phases of coagulation. This inhibition of thrombin generation was not mediated by protamine inhibition of contact activation, as corn trypsin inhibitor, which eliminates the contribution of contact pathway activation to thrombin generation in this system, had no effect on the observed reduction in thrombin generation (data not shown).

**Anticoagulant effects of protamine in reversal of heparin-induced anticoagulation**

Pharmacologic dose UFH (0.3 U/mL or 1 IU/mL) reduced the ETP such that no thrombin generation was detectable (Figure 3A). Protamine initially reversed the anticoagulant effect of UFH, resulting in a progressive increase in TF-initiated thrombin generation (Figure 3A). However, addition of higher concentrations of protamine to heparinized plasma resulted in a significant progressive reduction in thrombin generation, to a minimum of 54% (± 14%) and 57% (± 10%) of normal plasma ETP for 0.3 and 1.0 IU/mL UFH, respectively (Figure 3A). Similarly, although protamine at low dose (5-20 μg/mL) completely reversed the anticoagulant effect of the LMWH tinzaparin (1.0 U/mL), higher doses of protamine (20-80 μg/mL) were again associated with a significant reduction in ETP (to 78% ± 1%). In contrast, titration of protamine into plasma containing LMWH enoxaparin (1.0 U/mL) failed to fully correct TF-initiated thrombin generation (maximum 80% ± 4%). Moreover, in plasma containing enoxaparin, higher doses of protamine resulted in a more marked anticoagulant effect than that observed with either UFH or tinzaparin, respectively, to 21% (± 2% of normal ETP) (Figure 3B).

**Anticoagulant effects of APC in plasma are enhanced by protamine**

APC down-regulates thrombin generation by inactivation of procoagulant cofactors FVα and FVIIIa. Moreover, we have recently demonstrated that FVα proteolysis by APC can be specifically modulated by another cationic polypeptide, platelet factor 4. Consequently, we hypothesized that the anticoagulant effects of cationic protamine might be mediated through a similar mechanism. As expected, APC (1.25-20 nM) alone caused a concentration-dependent prolongation in APTT (maximum 2.8 ± 0.1-fold prolongation) in normal plasma (Figure 4A). However, the anticoagulant activity of APC on the APTT was markedly enhanced at all concentrations in the presence of protamine (30 μg/mL; Figure 4A). Furthermore, in keeping with the observed APTT findings, pharmacologic doses of protamine also significantly enhanced APC attenuation of TF-initiated thrombin generation. For example, although 1 nM APC alone had minimal effect on thrombin...
generation, coincubation of the same APC concentration with protamine (30 μg/mL) entirely ablated thrombin generation in normal plasma (Figure 4B). A synergistic anticoagulant interaction between APC and protamine was also observed in heparinized plasma. In the presence of 1 nM APC, the ability of high protamine concentrations to inhibit thrombin generation was markedly enhanced, such that thrombin generation was entirely ablated at 40 μg/mL protamine (Figure 4C).

Protamine does not enhance FVa or FVIIIa proteolysis by APC

To further elucidate the mechanism(s) through which protamine enhances APC anticoagulant activity, the rate of FVa proteolysis in the presence or absence of protamine was determined using a phospholipid-dependent FVa proteolysis time course assay (Figure 5A). In this purified system, the ability of APC to cleave and inactivate procoagulant FVa was not significantly enhanced in the presence of pharmacologic concentrations of protamine. Therefore, to determine whether the anticoagulant activity of protamine was due to enhanced FVIIIa proteolysis by APC, we assessed thrombin generation in FVIII-deficient plasma in the presence of an APC-resistant FVIII variant (R336Q/R562Q).18 Wild-type or variant FVIII in FVIII-deficient plasma entirely restored ETP to normal plasma levels (Figure 5B). Although low-dose protamine (3 μg/mL) did not significantly reduce ETP, a marked anticoagulant interaction was again observed when protamine was combined with APC (10 nM). Moreover, the synergistic anticoagulant effects of APC in combination with protamine were comparable for wild-type FVIII and for APC-resistant FVIII, suggesting that accelerated FVIIIa proteolysis is not responsible for the enhanced anticoagulant effects of APC in the presence of protamine.

Protamine inhibits activation of FV by α-thrombin and FXa

We further investigated whether protamine enhancement of APC in plasma was due to inhibition of FVía generation. In the presence of pharmacologic concentrations of protamine (50 μg/mL), activation of FV by thrombin (1 nM) was entirely ablated (Figure 6A). Moreover, low concentrations of protamine (0.25-12.5 μg/mL) significantly attenuated FV activation in a dose-dependent manner.
The 50% inhibitory concentration for protamine inhibition of FV activation by thrombin was only 0.8 mg/mL. Consequently, this effect is of clear clinical importance, given that peak protamine plasma concentrations can potentially reach 50 mg/mL after a single 50-mg bolus administration. Although physiologic activation of FV is predominantly mediated by thrombin, FXa can also activate FV. Interestingly, however, in the presence of protamine (50 mg/mL), FV activation by FXa (20 nM) was also significantly reduced (Figure 6C).

Preactivation of FV eliminates protamine anticoagulant effect in plasma

Previous studies have suggested that protamine may influence several different procoagulant and anticoagulant reactions in plasma. To determine the relative importance of protamine inhibition of FV activation in mediating the anticoagulant effect of protamine in plasma, increasing concentrations of either FV or FVa (0-20 nM) were titrated into FV-deficient plasma in the presence or absence of protamine (30 mg/mL; Figure 7). In a TF-initiated thrombin generation assay, addition of FV or FVa resulted in a significant increase in thrombin generation (Figure 7A-B). In keeping with our previous findings, protamine (30 mg/mL) significantly inhibited thrombin generation at all concentrations of FV (Figure 7A). However, in the presence of preactivated FVa, the ability of protamine to significantly inhibit thrombin generation was no longer evident (Figure 7B). Cumulatively, these data support the hypothesis that protamine-mediated inhibition of FV activation plays a critical role in mediating its anticoagulant activity in human plasma.

Discussion

Protamine sulfate is widely regarded as the treatment of choice for reversing UFH-induced anticoagulation. However, excessive protamine administration has been associated with anticoagulant activity, and has been implicated in the etiology of perioperative bleeding for many years. In particular, previous trials have demonstrated that the use of lower doses of protamine for heparin neutralization in patients after CPB resulted in reduced postoperative bleeding.

In a prospective study, Despotis et al randomized 254 patients requiring CPB to heparin neutralization with either a fixed dose of protamine (0.8 mg of protamine per mg total UFH), or a titrated protamine dosing based upon residual plasma heparin concentration. Although patients in the titrated protamine dosing arm of the study received lower doses of protamine, they developed fewer bleeding complications and required significantly lower doses of protamine than those in the fixed-dose arm. These findings suggest that titrated protamine dosing may be a more effective strategy for preventing bleeding after CPB.

In conclusion, protamine-mediated inhibition of FV activation plays a critical role in mediating its anticoagulant activity in human plasma. Further studies are needed to investigate the mechanisms underlying this anticoagulant effect, as well as to determine the optimal dosing strategy for protamine in the clinical setting.
less hemostatic support (platelets, fresh frozen plasma, and cryoprecipitate transfusions) during the perioperative period. Similarly, another prospective randomized trial of adult patients undergoing CPB also demonstrated that reduction in protamine dose was associated with significantly decreased mediastinal blood loss (50%).

In this study, we investigated the molecular mechanisms responsible for these clinically important protamine-mediated anticoagulant effects. We demonstrate that in vivo administration of protamine significantly reduces thrombin generation in murine plasma, and significantly prolongs tail-bleeding time. Moreover, protamine also has anticoagulant activity in normal human plasma. At pharmacologic doses (10 g/mL), protamine prolonged both the PT and APTT, suggesting an effect on the common pathway. Furthermore, protamine also significantly attenuated TF-initiated thrombin generation in human plasma.

Conversion of pro-cofactor FV to active FVa occurs early in the process of TF-initiated coagulation. Initial activation of FV by thrombin involves limited proteolytic cleavage of peptide bonds at Arg709, Arg1018, and Arg1545. FVa then associates with FXa on negatively charged phospholipid membrane surfaces to form the prothrombinase complex. In this complex, FXa acts as a critical cofactor, enhancing the ability of FXa to convert prothrombin to thrombin by 300 000-fold. In addition, FXa binding also makes FXa refractory to inhibition by anticoagulant tissue factor pathway inhibitor. Using purified protein assays to study the anticoagulant activity of protamine, we demonstrate that FV activation by thrombin is reduced in a dose-dependent manner by protamine. Moreover, this novel specific inhibitory effect upon FV activation is responsible for the bulk of the anticoagulant effect of protamine on TF-initiated thrombin generation in human plasma. Indeed, protamine had only a minor inhibitory effect on thrombin generation in plasma containing preformed FVa rather than pro-cofactor FV. Further studies will be required to unravel the precise mechanism(s) through which protamine attenuates activation of FV. Nevertheless, the observation that FV activation by both thrombin and FXa is inhibited indicates protamine may form an inhibitory complex with FV.

Because arginine residues account for approximately 60% of its primary amino acid sequence, protamine is highly cationic. Interestingly, several recent studies have shown that specific anionic molecules have the opposite effect to protamine on FV activation. Polyphosphate, a linear polymer of inorganic phosphate present in the dense granules of human platelets, significantly enhanced the rate of FV activation by both thrombin and FXa. Similarly, AV513, a sulfated proteoglycan of plant origin, has been shown to accelerate thrombin generation in plasma containing preformed FVa rather than pro-cofactor FV. Further studies will be required to unravel the precise mechanism(s) through which protamine attenuates activation of FV. Nevertheless, the observation that FV activation by both thrombin and FXa is inhibited indicates protamine may form an inhibitory complex with FV.
support the hypothesis that charge-mediated interactions may be critical in regulating FV activation.

Previous studies have reported that protamine can also down-regulate coagulation by directly inhibiting thrombin activity. However, high protamine concentrations (> 100 μg/mL) were only associated with relatively minor reductions in thrombin function. Moreover, at pharmacologic concentrations (≤ 50 μg/mL), we observed no significant protamine effect on thrombin clotting time, or thrombin amidolytic activity (data not shown). In contrast, the presence of 10 μg/mL protamine in pooled normal plasma was sufficient to prolong both the PT and APTT. In addition, the lag time and TTP of TF-initiated thrombin generation were significantly prolonged by 3 μg/mL protamine. Consequently, our findings clearly indicate that direct thrombin inhibition plays a relatively minor role in mediating the anticoagulant function of protamine. More recently, Nielsen demonstrated that clinically encountered protamine concentrations also resulted in enhanced fibrinolysis. Although the mechanism(s) responsible for this effect was not defined, these data would be consistent with a down-regulation in thrombin generation, and consequent reduction in thrombin-activatable fibrinolysis inhibitor activation.

The ability of pharmacologic doses of protamine to markedly inhibit FV activation has several direct important translational implications. First, the ACT assay is routinely used to monitor UFH-induced anticoagulation during cardiac surgery, and to evaluate the efficacy of protamine reversal during the immediate postoperative period.5 In other patients, including those presenting with life-threatening bleeding complications, heparin reversal after protamine administration is typically assessed using an APTT assay. However, as we have shown, administration of excess protamine significantly inhibits FV activation, thereby prolonging both the ACT and APTT, respectively. Consequently, an increased ACT or APTT after protamine administration cannot be regarded as pathognomonic of inadequate heparin reversal, but rather may reflect excess free protamine. Interestingly, we observed that TF-initiated thrombin generation curves could rapidly and reliably differentiate between residual heparin and excess protamine, suggesting a potential new diagnostic application for calibrated automated thrombography in this setting.

Second, our findings have important clinical implications in relation to the use of protamine for reversing LMWH-induced anticoagulation. Although protamine reverses the antithrombin activity of LMWH, it only partially neutralizes FXa inhibition. Consequently, as we demonstrate in this study, protamine is more effective in reversing the anticoagulant activity of LMWH with lower anti-FXa:antithrombin ratios (eg, tinzaparin 2:1 compared with enoxaparin 3:1). However, we further demonstrate that rather than reversing LMWH-induced anticoagulant properties, administration of high protamine concentrations actually serves to further enhance the anticoagulant status. Furthermore, this phenomenon is more apparent in the presence of enoxaparin rather than tinzaparin, and presumably reflects residual LMWH anti-FXa activity, coupled with the inhibitory activity of excess free protamine on FV activation. Interestingly, an even more marked combined anticoagulant response was observed when protamine was titrated into plasma containing the low molecular weight heparinoid danaparoid (anti-FXa:antithrombin ratio 28:1; data not shown). Further adequately powered clinical studies will be required to define the clinical utility of protamine in reversing the anticoagulant effects of LMWH. Finally, although protamine does not directly enhance the proteolytic activity of APC, nevertheless, the combination of protamine and APC does result in a potent synergistic anticoagulant effect. Consequently, our data suggest that protamine administration should be used with caution in patients with severe sepsis receiving recombinant APC by continuous infusion.

Acknowledgments

This work was supported by Molecular Medicine Ireland Clinician Scientist Award G04005 (to F.N.A.); Health Research Board Ireland Project Grant Award RP/2006/44 (to J.S.O.); Health Research Board Ireland Postdoctoral Fellowship PD/2006/24 (to R.J.S.P.); an Irish Heart Foundation grant (to J.S.O.); and Science Foundation Ireland President of Ireland Young Researcher Award 06/Y12/0925 (to J.S.O.).

Authorship

Contribution: F.N.A. designed the research, performed experiments, analyzed results, made the figures, and wrote the paper; R.J.S.P. designed and supervised the research, analyzed results, and wrote the paper; P.V.J. and H.J.N. performed experiments and analyzed results; J.A.J. performed experiments; O.P.S. and B.W. supervised the research; P.G.F. designed and supervised the research; and J.S.O. designed and supervised the research and wrote the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: James S. O’Donnell, Hemostasis Research Group, Trinity Health Center, St James’s Hospital, James’s St, Trinity College, Dublin, Ireland; e-mail: jodonne@tcd.ie.

References


Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation

Fionnuala Ni Ainle, Roger J. S. Preston, P. Vincent Jenkins, Hendrik J. Nel, Jennifer A. Johnson, Owen P. Smith, Barry White, Padraic G. Fallon and James S. O'Donnell